It is well recognized that cAMP has important and multiple regulatory roles in the development and function of many different cells. It is also known that cAMP, works largely through activation of cAMP-dependent protein kinases and/or the guanine nucleotide exchange protein, Epac. Moreover, in the last few years it has become clear that specific compartments are present in most cells that serve to organize and regulate specific cAMP-dependent processes in the cells. One of the most important mechanisms by which this regulation occurs is through selective activation or inhibition of distinct isozymes of cyclic nucleotide phosphodiesterases (PDEs) in the cell. Although over 100 different PDEs are known, any single cell type usually expresses less than half a dozen of them and any single compartment even fewer. Our current understanding is that a very small number of PDEs will serve to control a particular pool of cAMP or cGMP. Therefore, different PDEs can easily regulate different processes in the cell. It is the goal of the proposed studies to identify in several different cell types which processes and proteins in that cell are regulated by PDE8A and PDE8B. The PDE8 family is a relatively newly discovered PDE family that is specific for cAMP and has the unusual property of being completely insensitive to isobutylmethylxanthine (IBMX), a highly effective small molecule inhibitor of all other PDEs of this class. As a result PDE8s have until recently not been implicated as major regulators of cellular function. However, recent data from our group now show that they can be very important to regulation of cell function. Our new data shows that in addition to Leydig cells, PDE8s are highly expressed in liver hepatocytes, brown fat cells, and adrenal fasciculata cells. Since we now have available mice having the PDE8A and PDE8B genes disrupted, we are in position to determine the importance of these two PDEs to cellular function, despite the fact that selective small molecule inhibitors are not yet available. Therefore, we propose to determine which of the several functions known to be modulated by cAMP in each of these cell types are regulated by this PDE family and how they do so.

Public Health Relevance

The proposed studies will explore the role of a newly discovered and previously unstudied family of cyclic nucleotide phosphodiesterases, the PDE8s on adrenal, liver, and brown fat function. Preliminary evidence suggests that these PDEs are major regulators of cAMP controlled functions in these cell types. It is expected that the proposed studies will tell us which processes are regulated and how the regulation occurs at the molecular level. Just as another specific form of PDE is the target of the drug Viagra, so also it is quite possible that PDE8s may become the targets of drugs useful for treating adrenal, liver and adipose tissue dysfunction once we understand how they function in each of these tissues.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM083926-04
Application #
8072053
Study Section
Molecular and Integrative Signal Transduction Study Section (MIST)
Program Officer
Dunsmore, Sarah
Project Start
2008-08-01
Project End
2012-05-31
Budget Start
2011-06-01
Budget End
2012-05-31
Support Year
4
Fiscal Year
2011
Total Cost
$290,502
Indirect Cost
Name
University of Washington
Department
Pharmacology
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Golkowski, Martin; Perera, Gayani K; Vidadala, Venkata Narayana et al. (2018) Kinome chemoproteomics characterization of pyrrolo[3,4-c]pyrazoles as potent and selective inhibitors of glycogen synthase kinase 3. Mol Omics 14:26-36
Golkowski, Martin; Vidadala, Rama Subba Rao; Lombard, Chloe K et al. (2017) Kinobead and Single-Shot LC-MS Profiling Identifies Selective PKD Inhibitors. J Proteome Res 16:1216-1227
Beltejar, Michael-Claude G; Lau, Ho-Tak; Golkowski, Martin G et al. (2017) Analyses of PDE-regulated phosphoproteomes reveal unique and specific cAMP-signaling modules in T cells. Proc Natl Acad Sci U S A 114:E6240-E6249
Shimizu-Albergine, Masami; Van Yserloo, Brian; Golkowski, Martin G et al. (2016) SCAP/SREBP pathway is required for the full steroidogenic response to cyclic AMP. Proc Natl Acad Sci U S A 113:E5685-93
Golkowski, Martin; Shimizu-Albergine, Masami; Suh, Hyong Won et al. (2016) Studying mechanisms of cAMP and cyclic nucleotide phosphodiesterase signaling in Leydig cell function with phosphoproteomics. Cell Signal 28:764-78
Egbert, Jeremy R; Uliasz, Tracy F; Shuhaibar, Leia C et al. (2016) Luteinizing Hormone Causes Phosphorylation and Activation of the cGMP Phosphodiesterase PDE5 in Rat Ovarian Follicles, Contributing, Together with PDE1 Activity, to the Resumption of Meiosis. Biol Reprod 94:110
Patrucco, Enrico; Domes, Katrin; Sbroggió, Mauro et al. (2014) Roles of cGMP-dependent protein kinase I (cGKI) and PDE5 in the regulation of Ang II-induced cardiac hypertrophy and fibrosis. Proc Natl Acad Sci U S A 111:12925-9
Kraynik, Stephen M; Miyaoka, Robert S; Beavo, Joseph A (2013) PDE3 and PDE4 isozyme-selective inhibitors are both required for synergistic activation of brown adipose tissue. Mol Pharmacol 83:1155-65
Rybalkin, Sergei D; Hinds, Thomas R; Beavo, Joseph A (2013) Enzyme assays for cGMP hydrolyzing phosphodiesterases. Methods Mol Biol 1020:51-62
Demirbas, Didem; Wyman, Arlene R; Shimizu-Albergine, Masami et al. (2013) A yeast-based chemical screen identifies a PDE inhibitor that elevates steroidogenesis in mouse Leydig cells via PDE8 and PDE4 inhibition. PLoS One 8:e71279

Showing the most recent 10 out of 22 publications